Calliditas Therapeutics AB is a high-risk biopharmaceutical company based in Sweden, specializing in pharmaceuticals. Their focus is on developing innovative treatments for orphan diseases, specifically targeting renal and hepatic conditions with unmet medical needs. Their pipeline includes TARPEYO medication designed to reduce proteinuria in IgA nephropathy. With an ESG score of 34.4, Calliditas Therapeutics AB is committed to environmental sustainability and governance practices.